Article Information
History
- January 10, 2022.
Article Versions
- You are currently viewing Version 1 of this article (January 10, 2022 - 13:06).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Madeleine D Burns1,
- Yannic C Bartsch, PhD2,
- Brittany P Boribong, PhD1,
- Maggie Loiselle1,
- Jameson P Davis1,
- Rosiane Lima1,
- Andrea G Edlow, MD3,
- Alessio Fasano, MD1,
- Galit Alter, PhD2,* and
- Lael M Yonker, MD1,*
- 1Massachusetts General Hospital Department of Pediatrics, Mucosal Immunology and Biology Research Center, Boston, MA, USA
- 2Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
- 3Massachusetts General Hospital Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Vincent Center for Reproductive Biology, Boston, MA, USA
- ↵*Corresponding authors: Lael M Yonker; LYONKER{at}mgh.harvard.edu; +1 (617) 724-2890 and Galit Alter, GALTER{at}mgh.harvard.edu, +1 (617) 233-1122
Posted January 10, 2022.
Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children
